Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 May;98(18):e15428.
doi: 10.1097/MD.0000000000015428.

Treatment of myoclonic-atonic epilepsy caused by SLC2A1 de novo mutation with ketogenic diet: A case report

Affiliations
Free PMC article
Case Reports

Treatment of myoclonic-atonic epilepsy caused by SLC2A1 de novo mutation with ketogenic diet: A case report

Zihan Wei et al. Medicine (Baltimore). 2019 May.
Free PMC article

Abstract

Rationale: The SLC2A1 gene encodes glucose transporter 1 on blood-brain barrier, which plays an important role in the energy supply for neurons. Mutations in SLC2A1 gene can cause many clinical syndromes, including glucose transporter type 1 deficiency syndrome and many types of epilepsy syndromes such as childhood absence epilepsy and myoclonic-atonic epilepsy, etc. Ketogenic diet has been proved to be very effective on those cases. Clinically, SLC2A1 gene mutations are quite rare.

Patient concerns: Repeated unconsciousness and bilateral limb weakness lasted for 3 years.

Diagnoses: Myoclonic-atonic epilepsy.

Lessons: After taking whole exome sequencing, we found out that there is a de novo insertion mutation in the patient's SLC2A1 gene, leading to frameshift. As a result, ketogenic diet (2:1, 4 times a day) was used as the treatment. As for the patient, total calories intake per day was controlled at 1190 kcal. The calories per kg per day were 66.11 kcal/kg. The amount of ketone bodies was controlled at 2 to 3 mmol/L and the concentration of plasma glucose was controlled at 4 to 5 mmol/L.

Outcomes: After the launch of ketogenic diet, the patient has been seizure free for nearly a year and stopped all his antiepileptic drugs.

Conclusion: Our case suggests that gene examination is very important part of the diagnosis of epilepsy etiology and epilepsy syndromes. Ketogenic diet should be considered as the first line therapy with SLC2A1 gene mutations.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interest.

Figures

Figure 1
Figure 1
Clinical evaluation processes we took after receiving the patient. (A) VEEGs during wakefulness. Unsynchronized sharp and spikeslow waves appeared. (B) Sleeping VEEGs. Generalized spike and slow waves during NREM sleep appeared. VEGG = video electroencephalography.
Figure 1 (Continued)
Figure 1 (Continued)
Clinical evaluation processes we took after receiving the patient. (A) VEEGs during wakefulness. Unsynchronized sharp and spikeslow waves appeared. (B) Sleeping VEEGs. Generalized spike and slow waves during NREM sleep appeared. VEGG = video electroencephalography.
Figure 2
Figure 2
The first row belongs to the patient. Compared with standard sequence of SLC2A1 gene, there are a mutation in the patient's gene, a 25 bp insertion mutation between c1094 and c1095 in exom 9. There are no mutations in his parents’ exome. The red boxes indicate the insertion in the proband and normal sequences in his parents.
Figure 3
Figure 3
VEEGs results after ketogenic therapy for 6 months. Only few slow sharp waves appeared in his VEEGs. VEGG = video electroencephalography.

Similar articles

Cited by

References

    1. Thorens B, Mueckler M. Glucose transporters in the 21st Century. Am J Physiol Endocrinol Metab 2010;298:E141–5. - PMC - PubMed
    1. Escary J, Cecillon M, Maciazek J, et al. Mutational analysis of GLUT1 (SLC2A1) in glut-1 deficiency syndrome; dong wang; pamela kranz-eble; darryl C. De vivo; (Article was originally published in human mutation 16:224-231, 2000). Hum Mutat 2000;16:527. - PubMed
    1. De Vivo DC, Trifiletti RR, Jacobson RI, et al. Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med 1991;325:703–9. - PubMed
    1. Klepper J. GLUT1 deficiency syndrome in clinical practice. Epilepsy Res 2012;100:272–7. - PubMed
    1. Koch H, Weber YG. The glucose transporter type 1 (Glut1) syndromes. Epilepsy Behav 2019;91:90–3. - PubMed

Publication types

Substances